

Real-world use of blinatumomab in adult ALL

NEUF study<sup>1</sup>

Population: N = 249



**Eligibility:** Patients with B-ALL treated with blinatumomab in an EAP; Jan 1, 2014 – Jun 30, 2017; France, Italy, Russian Federation, Spain, UK.

**MRD+ group (n = 109)**  
Ph– (n = 83);  
median age, 35.0 years  
Ph+ (n = 26);  
median age, 50.5 years

**R/R group (n = 140)**  
Ph– (n = 106);  
median age, 36.5 years  
Ph+ (n = 34);  
median age, 51.0 years

EFFICACY<sup>1</sup>

Response rates within first two cycles of therapy



Additional real-world studies

**Urbino, et al.<sup>2</sup>**      **Population: N = 115**

**Eligibility:** Patients with B-ALL treated with blinatumomab; Apr 2012 - Jun 2021; at Saint-Louis University Hospital, Paris, France, or Città della Salute e della Scienza University Hospital, Turin, Italy.



Median age, 37 years; median cycles, 2  
CR1 (n = 68), CR2 (n = 31), R/R (n = 16)

**Zhou, et al.<sup>3</sup>**      **Population: N = 96**

**Eligibility:** Patients with B-ALL treated with blinatumomab; Aug 2021 – Jun 2023; from electronic medical data of the Dept of Hematology at the First Affiliated Hospital of Soochow, Suzhou, China.

Median age, 34 years; median cycles, 1  
ND (n = 53), R/R (n = 43)

EFFICACY



Results from the NEUF study and other real-world studies confirm the efficacy of blinatumomab in patients with B-ALL, including MRD+ patients, R/R patients, patients in CR1 and CR2, and ND patients.

**Abbreviations:** ALL, acute lymphoblastic leukemia; B-ALL, B-cell ALL; CR, complete remission; CR1, first CR; CR2, second CR; CRh, CRh, CR with partial hematologic recovery; CRi, CR with incomplete count recovery; DFS, disease-free survival; EAP, expanded access program; EFS, event-free survival; MRD, measurable residual disease; ND, newly diagnosed; NE, not evaluable; NR, not reached; OS, overall survival; Ph, Philadelphia chromosome; RFS, relapse-free survival; R/R, relapsed/refractory.

1. Boissel N, et al. Blood Cancer J. 2023;13(1): 2. Urbino I, et al. Blood Adv. 2024;8(10):2405-2409. 3. Zhou H, et al. Invest New Drugs. 2024;42(3):299-308.